Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes? by Cserni, G&#225 et al.
SHORT COMMUNICATION
Is Regression after Neoadjuvant Chemotherapy for Locally
Advanced Breast Cancer Different in Sentinel
and Non-sentinel Nodes?
Gábor Cserni1,2 & Tamás Zombori2 & Xavier Andreu3 & Simonetta Bianchi4 &
Peter Regitnig5 & Isabel Amendoeira6 & Davide Balmativola7 & Anikó Kovács8 &
Alicia Cordoba9 & Angelika Reiner10 & Janina Kulka11 & Handan Kaya12 &
Inta Liepniece-Karele13 & Cecily Quinn14 & Bence Kővári2
Received: 3 March 2017 /Accepted: 3 April 2017 /Published online: 8 April 2017
# Arányi Lajos Foundation 2017
Abstract Tumor draining sentinel lymph nodes (SLNs) are
the sites of selective changes as compared to non-SLNs. They
show features of tumor-reactive lymphadenopathy, including
increased total number of functional blood vessels, but a rel-
ative immunosuppressed status has also been described in
them. We explored the hypothesis of a selective regression
or non-regression in SLNs versus non-SLNs in 142 patients
with 110 estrogen receptor-positive and 32 estrogen receptor-
negative tumors undergoing both SLN biopsy and axillary
lymph node dissection after neoadjuvant therapy by assessing
the tumoral (metastatic) and regression statuses of SLNs and
non-SLNs separately. Of the 89 cases with signs of nodal
regression, 22 cases (25%) were in favor of a selective non-
regression in SLNs, 18 cases (20%) were supportive of a se-
lective and more pronounced regression in the SLNs and the
remaining showed equal degrees of regression or non-
regression in SLNs and non-SLNs. The results indicate that
there is no obvious difference in the degree of regressive his-
tological changes shown by SLNs and NSLNs. Therefore, this
phenomenon may not be a major contributor to the higher
false negative rate of SLN biopsy after neoadjuvant treatment.
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Introduction
Lymph nodes are not identical. The sentinel lymph nodes
(SLN) are the first lymph nodes draining the lymph from an
anatomical site and therefore, in case of a cancer in the given
area, the SLNs are the first involved during the lymphatic
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spread of cancer. The non-SLNs of the same anatomic region
develop metastases only subsequently. Development of metas-
tasis is not the only change known to occur in tumor draining
lymph nodes. Tumor-reactive lymphadenopathy (TRL) is a
complex reaction of lymph nodes, which develops before the
arrival of the metastatic tumor cells and comprises morpholog-
ical and functional changes. Enlargement of the tumor draining
lymph nodes (also induced by needle biopsy of the primary
cancer) has helped axillary four-node sampling [1], and may
explain the possible overlap of axillary node samples and sen-
tinel nodes [2]. As concerns the morphological alterations, pre-
vious publications found increased total number of functional
blood vessels and lymphatic vessels/sinuses in tumor draining
lymph nodes. Furthermore, some authors have described dila-
tion of functional blood vessels with structural remodeling and
endothelial cell proliferation of high endothelial venules [3].
Functional changes, such as increased blood perfusion and im-
munological differences, like the alterations in CD28 and
CD3ζ expression of CD4+ and CD8+ T-lymphocytes [4, 5]
or the reduction in density and dendritic complexity of antigen
presenting paracortical dendritic cells [6] were also observed in
tumor draining lymph nodes. Tumor-induced immune modu-
lation of the SLNs versus the non-SLNs seems to act in favor of
a reduced anti-tumoral immune reaction [6].
The above-mentioned factors may hypothetically alter the
neoadjuvant therapy induced reactions in tumor-draining
SLNs compared to lymph nodes without direct connection
with the primary carcinoma, i.e. non-SLNs. Enhanced blood
flow and enriched vasculature may increase the load of che-
motherapeutics or targeted cancer therapy agents (e.g. hor-
mone receptor modulators or trastuzumab) in lymph nodes
developing TRL. A preferential regression in SLNs might
influence the false negative rate of SLN biopsy after primary
systemic treatment, by resulting in complete regression in
SLNs with remaining tumor burden in non-SLNs.
Alternatively an immunosuppressed status of the SLNs as
compared to non-SLNs could lead to less effect from cytotox-
ic therapeutics. A selective regression or non-regression may
also alter the staging effect of the removal of radioactive seed
localized nodes that proved to be positive before the initiation
of primary systemic treatment [7].
Along this hypothesis, differences in the degree of regression induced
byneoadjuvant therapyin theSLNs(tumordraining lymphnodes)and in
non-SLNs (non-tumor draining lymphnodes)were looked for in a series
of patients who underwent SLN biopsy and axillary lymph node dissec-
tion (ALND) following neoadjuvant systemic therapy for breast cancer.
Materials and Methods
In this retrospective study, lymph node tissue sections
of 142 female breast cancer patients staged with SLN
biopsy and ALND after receiving neoadjuvant therapy
were used from the archives of the authors’ institutions.
Inclusion criteria for enrollment were any type of histo-
logically verified invasive primary breast cancer treated
with neoadjuvant systemic therapy, the successful iden-
tification of at least one SLN and ALND following
SLN biopsy. SLNs were identified according to the rou-
tine procedure of the given institutions, and involved
intra- or peritumoral or subareolar injection of a
99mTc labelled colloidal albumin and/or Patent blue
dye in vivo. ALND was performed either routinely as
part of a validation of SLN biopsy after neoadjuvant
treatment or because of metastatic disease identified in
the SLNs.
Tissues were fixed in buffered formalin and embed-
ded in paraffin. Three to four-micrometer-thick whole
tissue sections were used for the standard hematoxylin-
eosin staining. The presence and degree of regression
were evaluated in all metastatic and non-metastatic
lymph nodes, SLNs and non-SLNs separately, using
the nodal regression (NR) grading recommended by
the European guidelines [8]. These results were used
to categorize the cases, based on whether they support-
ed the theory that regression in SLNs may be greater
than in NSLNs or not (Table 1). The table reflects the
nodes with the best/highest degree of regression for
each case.
No patient identity related data were required or used, dis-
ease outcome was indifferent for the study purposes, and this
retrospective non-interventional setting had no influence on
treatment. Such a protocol does not imply an ethical approval
in most of the participating institutions, but the Ethical
Committee and Data Safety Manager of Bács-Kiskun
County Teaching Hospital, where the study was initiated,
were consulted and no ethical concerns were raised
(Reference Number: 4/170125).
Results
The mean (±S.D.) age of the patients was 50.2 (±11.0)
years. A median of 2 SLNs (range: 1–8) and 14 non-
SLNs (range: 2–42) were removed from the patients.
The neoadjuvant treatment involved hormonal therapy
with aromatase inhibitors in 10 cases, whereas the re-
maining patients received chemotherapies. There were
110 estrogen receptor (ER) positive tumors (including
25 human epidermal growth factor receptor 2 – HER2
positive cases), and of the 32 ER negative tumors, 12
were HER2 positive by immunohistochemistry or in situ
hybridization. Complete primary tumor regression with
or without residual in situ carcinoma was seen in 24
cases, and no signs of regression were reported in 16
primary cancers. No nodal regression at all was
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evidenced in 19 node-positive cases, whereas 55 cases
had at least one metastatic lymph node without evidence
of regression (NR4). The metastasis and regression sta-
tus of the analyzed cases are summarized in Table 1.
Categories B, C0, F, H, I, J and N represented 87/142 cases
including 40 node-positive cases without evidence of regres-
sion in the lymph nodes (Table 1), and were indifferent to-
wards the tested hypothesis. Of the 89 cases with signs of
nodal regression, the 22 cases in categories A, C2, E and G,
where the regression was of greater degree in non-SLNs (22/
89 cases, 25%) were in favor of a selective non-regression in
SLNs. Only 18/89 cases (20%) fell into categories C1, D or K,
and were in support of a selective and more pronounced re-
gression in the SLNs.
Discussion
The practice of SLN biopsy in locally advanced breast cancer
patients receiving neoadjuvant systemic treatment is still
somewhat controversial. Often the SLN biopsy was per-
formed before primary systemic therapy or was not performed
because of previously evidenced metastatic lymph nodes. The
required cases were relatively rare in our archives, and the
present study should be regarded as an exploration of the
theory of a potential selective regression (or non-regression)
in SLNs.
There are some reservations regarding the possible
conclusion of the study. The methods of SLN biopsy
were obviously not uniform, but were the ones applied
and relied on in clinical practice at the given institution.
The nature of the therapeutic agents used for primary
systemic treatment could not be taken into account, as
there was a wide variation in the protocols and drugs
used, and the low case numbers would not have made
any treatment-specific analysis possible. Altogether the
case numbers are relatively small, however, the distribu-
tion of the cases did not point in favor or against a
selective regression (or non-regression) in SLNs.
Finally, fibrotic foci in the lymph nodes were interpreted
as signs of regression, but these signs are not specific,
and other processes may lead to the same morphological
features. However, in the setting of neoadjuvant therapy,
this latter is the most likely cause for these morpholog-
ical changes, and therefore these were uniformly
interpreted as signs of regression.
The evidence gathered from the limited number of cases
available suggests that despite the attractiveness of a preferen-
tial regression (or non-regression) in tumor draining lymph
nodes (SLNs which seem to be immunosuppressed and at
the same time are the sites of TRL), there is no obvious dif-
ference in the degree of regressive histological changes shown
by SLNs and NSLNs. Therefore, this phenomenonmay not be
a major contributor to the somewhat higher false negative rate
of SLN biopsy after neoadjuvant treatment [9].
Table 1 Categorization of the results on the basis of possible variations in the distribution of metastases and regression and their relation to the theory
of a possible selective regression pattern in SLNs
SN metastasis SN regression NSN metastasis NSN regression Category Relation to theory No. of cases
Yes Yes No Yes A Against 9
No B Indifferent 15
Yes Yes (= SN) C0 Indifferent 8
Yes (< SN) C1 In favor 11
Yes (> SN) C2 Against 5
No D In favor 6
No No Yes E Against 3
No F Indifferent 24
Yes Yes G Against 5
No H Indifferent 18
No Yes No Yes I Indifferent 11
No J Indifferent 2
Yes Yes K In favor 1
No L In favor 0
No No Yes M False negative SLN 7
No N Indifferent 9
Yes Yes O False negative SLN 6
No P False negative SLN 2
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